CN1838970A - Antioxidant wound dressing materials - Google Patents
Antioxidant wound dressing materials Download PDFInfo
- Publication number
- CN1838970A CN1838970A CNA2004800238156A CN200480023815A CN1838970A CN 1838970 A CN1838970 A CN 1838970A CN A2004800238156 A CNA2004800238156 A CN A2004800238156A CN 200480023815 A CN200480023815 A CN 200480023815A CN 1838970 A CN1838970 A CN 1838970A
- Authority
- CN
- China
- Prior art keywords
- wound dressing
- dressing materials
- silver
- antioxidant
- dyestuff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/56—Wetness-indicators or colourants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
- A61F13/064—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings for feet
- A61F13/069—Decubitus ulcer bandages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, chitosan or oxidized regenerated cellulose, and the dyestuff may for example be an aniline or acridine dye. The material preferably also comprises a silver salt, whereby the dyestuff stabilizes the silver salt. Also provided are methods of making such materials, and wound dressings comprising such materials.
Description
The present invention relates to antioxidant wound dressing materials, be suitable for preparing the method for this class material and the application of this class wound dressing materials.
Reactive oxygen species, such as hydroxyl radical free radical (OH), singlet oxygen (
1O
2), hydroperoxy radical (OOH), superoxide radical anion (O
2 -) and hydrogen peroxide (H
2O
2) concentration can in damaged tissues, raise, thereby produce the condition of reorganization oxidative stress.Low-level reactive oxygen species exist by attract and activation engulf and kill and wound antibacterial and discharge cytokine and commitment that the macrophage of somatomedin cicatrizes a wound in be favourable.Yet, prolong and more serious oxidative stress can delayed healing, because it can produce chronic inflammatory disease, shift available energy to the antioxidant defence supply with and increase the level that causes histolytic matrix metalloproteinase under the situation of loss tissue reconstruction.In even more serious situation, the reactive oxygen species of elevated levels can produce aging or the programmed cell death (being programmed cell death) or the tissue necrosis (being uncontrollable cell death and nonvolatil thus tissue injury) of hydrogen peroxide-induced.
Under mild oxidative stress, think hydrogen peroxide (H
2O
2) be the dominant species that exists, it is formed by superoxides fast by hemocuprein.The disproportionation of this kind of enzyme mediation is also minimized the generation of singlet oxygen, and described singlet oxygen can and have an opportunity in the too fast generation of superoxides not produce when having enzyme to assist spontaneous disproportionation thus.The superoxides disproportionation of enzyme mediation is also with hydroperoxy radical fast, and promptly the level of superoxides nonionic form is reduced to minimum.The level of hydrogen peroxide is maintained by the effect of catalase and glutathion peroxidase thus.Therefore, under the mild oxidative stress condition, when the hydrogen peroxide level slightly rises (10
-8-10
-4About mole) time, find that the cell proliferation rate in the fibroblast cell cultures is upset.
Therefore, can assist the chronic wounds healing by using antioxidant wound dressing, described antioxidant wound dressing special with excessive reactive oxygen species, such as above-mentioned those listed reactions, and reduce the level of oxidative stress thus.
The compositions of chemical modification polymer of chemical group that comprised grafting has been described among the US-A-5667501, described chemical group provide as the antioxidant activity of being measured in diphenylpicrylhydrazyl (DPPH) test and by with wound bed portion in the molecular oxygen reaction produce low-level hydrogen peroxide so that stimulate macrophage activity and fibroblast proliferation.These compositionss can be used to promote the chronic wounds healing.Preferred described polymer is the polysaccharide that has the polymer of hydroxyl, carbonyl or amide functional base or be lower than the hydroxyl-functional base, described functional group has been converted to the derivant of persistency free radical or persistency free radical precursor, and promptly they are for removing the free radical of antioxidant group.
The compositions that comprises polysaccharide has been described among the US-A-5612321, described polysaccharide at least one hydroxyl of this polysaccharide grafting antioxidant.These compositionss can be used to promote the chronic wounds healing especially.Preferred described polysaccharide is that hyaluronic acid and described antioxidant group comprise phenolic group.
Above-mentioned antioxidant wound dressing materials, is made such as hydroquinones or benzimidizole derivatives and matrix material covalent bond so that the antioxidant part by the multistep chemical reaction.Still there is demand to obtaining the more easy and cheap approach of antioxidant wound dressing materials.
The wound dressing that contains the antibacterial that is used for the treatment of wound infection also is known.The preferred antimicrobial agents that is used for wound dressing at present is some antiseptic, such as chlorhexidine and triclosan, and silver, no matter be form of film, nanoparticle, or collargol.The chemical compound of silver is also as antibacterial.For example, following complex silver salts can be advantageously used in antiallergic perception and tolerant bacteria bacterial strain: silver sulfadiazine, norfloxacin silver (silver norfloxacinate), pipemidic acid silver, Kaolin silver, ethylenediaminetetraacetic acid silver, thiosalicylic acid silver and silver chloride imidazoline.
The application of alginic acid silver salt in wound dressing described among the WO91/11206.
The hyaluronic silver salt that can be used as or be used for antibacterial wound dressing has been described among the WO87/05517.These materials trend towards instability having in the presence of the light.Silver hair third contact of a total solar or lunar eclipse electronation and independent argent causes material deepening in a period of time.
Described the stable antibacterial wound dressing material of light among the WO02/43743, wherein the light stabilizer that is selected from ammonium salt, thiosulfate, metal chloride and peroxide by interpolation makes silver salt stable.Described the stable antibacterial wound dressing material of light among the WO97/02038, wherein made silver salt stable by adding polyether polymer.This class light stabilizer has limited effect, and trends towards being extracted out from described dressing materials by the wound fluid.
Therefore, still there is demand in the improved antiseptic dressing that contains the stable silver compound of light.
Calcium alginate as wound dressing has been described among the GB-A-619165.Antibacterial or Fungicidal compounds can be administered on the silk after their form such as acridine derivatives or eusol, maybe can join from wherein extracting out the solution of silk.Calcium alginate is not biological absorbable.
Described chitosan films, rod, sheet, medicated bandage, patch etc. among the EP-A-0368253, they are made by the solution or the mixture of some chitosan derivative and antibacterial.Still unexposedly can absorb wound dressing materials with antioxidant dyestuff dyeing biology.
The present invention provides wound dressing materials in aspect first, but comprises with the painted solid biologic absorption base of antioxidant dyestuff.
It is treated that term " painted " refers to the surface, and using the solid-state solid material that makes this dyestuff and surface combination down of dyestuff.Promptly after curing, carried out the solid material of post processing with dyestuff.But have been found that biology absorption base material, to antioxidant dyestuff, have splendid affinity such as phenyl amines and acridine dye such as oxidized regenerated cellulose.This characteristic can make the fixing of dye of controlled amounts on host material according to simple and cheap staining procedure.Further find that the painted material of gained has kept the antioxidant properties of this dyestuff, make them become the material standed for that treatment chronic wounds and further feature are the wound that the oxygen-derived free radicals level raises thus.These materials have useful antibacterial characteristics, particularly resisting gram-positive bacteria, and also anti-sometimes gram negative bacteria.Bioabsorbable material progressively decomposes the slow release of having realized the effective dose antibacterial in wound.
Term " biological absorbable host material " refers to the solid material of degrading fully and absorbing in mammalian body.This term does not comprise cellulose or textile material commonly used thus.This host material is water insoluble usually, but can be for water-swellable.In certain embodiments, substrate comprises (and mainly being grouped into by following one-tenth) solid biologic absorbable material, and this material is selected from following material: collagen protein; Chitosan; The plain derivant of bio-absorbable fibers is such as oxidized cellulose; Galactomannan is such as sugar/borate; Glycosaminoglycans is such as cross-linked-hyaluronic acid salt; Polylactide class/poly-Acetic acid, hydroxy-, bimol. cyclic ester class; The poly butyric esters; And composition thereof.
In certain embodiments, described substrate comprises that (and mainly being grouped into by following one-tenth) is selected from the solid biologic absorbable material of collagen protein, chitosan, oxidized regenerated cellulose and composition thereof.
For example, by producing oxidized cellulose with the dinitrogen tetroxide oxidized cellulose.This method changes into carboxylic moiety with the primary alconol base on the saccharide residue, thereby forms uronic acid residue in cellulose chain.This oxidation is not carried out with complete selectivity, and the result is that 2 and 3 hydroxyls on the carbon are converted to the ketone group form sometimes.Alkaline labile bond has been introduced in these ketone unit, and it separates the beginning decomposing copolymer by forming lactone and sugared ring crack when pH7 or pH7 are above.As a result of, oxidized cellulose is biodegradable and biological absorbable under physiological condition.
The preferred oxidized cellulose that is used for practical application is the cellulose by oxidation regeneration, such as the oxidized regenerated cellulose (ORC) of artificial silk preparation.Known for a period of time ORC has haemostatic properties and uses the degree that the ORC fabric can be used for alleviating the abdominal surgery tissue adhesion.
Can obtain oxidized regenerated cellulose (ORC) by method described in the US-A-3122479, the full content of the document is incorporated herein by reference.This material provides a large amount of advantages, comprises biocompatibility, biodegradable, non-immunogenic and the spy who is easy to be purchased.Can obtain having the ORC of different degree of oxidations and consequent degradation rate.Can use ORC with the form of insoluble fibre, comprise textile fabric, adhesive-bonded fabric and knitted fabric.
In certain embodiments, described oxidized cellulose is a particle form, such as fiber grain or powdered granule, they is scattered in suitable solid or the semi-solid topical medicament vehicle.Especially, these materials preferably contain the ORC fiber, and wherein the length that has of the fiber of at least 80% volume fraction is in the scope of 20 μ m-1000 μ m.For example, can the powder that grinds be sieved obtain to treat size distribution to remove this extraneous fiber subsequently by grinding ORC cloth, average (volume averaging value) length of preferred ORC fiber is in the scope of 250 μ m-450 μ m.In this scope, select the ORC fibre length to be easy to mix ORC and other composition, and produce product highly uniformly.ORC is compound with other composition more fully, causes the treatment characteristic of sponge to strengthen.
Preferred described oxidized cellulose has the mean molecule quantity greater than 50,000.This class oxidized cellulose is insoluble to the wound fluid basically, can absorb fragment but can resolve into biology very step by step under physiological pH.Described oxidized cellulose can be for neutral for its free acid form or it.For example, the present invention includes the partially or completely application of neutral material described in EP-A-0437095, the full content of the document is incorporated herein by reference.For example, as hereinafter more specifically as described in, ORC can partly be neutralized such as silver acetate by faintly acid silver salt.
In certain embodiments of the invention, described oxidized cellulose and collagen protein and/or chitosan are combined into the structure of type described in WO98/00180, WO98/00446, EP-A-1153622 or the WO2004/026200, and the full content with these documents is incorporated herein by reference especially.For example, described oxidized cellulose can be for being scattered in the ORC fibers form of the grinding in the cryodesiccated collagen protein sponge.This situation provide because of with compound certain treatment and the synergism that produces of collagen protein.
If use, the collagen protein in the material so of the present invention can be collagen protein arbitrarily, comprises I type, II type or III collagen type; Natural fibrous collagen; Atelocollagen; The collagen protein of partial hydrolysis is such as gelatin; And combination.Natural fibrous collagen, the natural fibrous collagen that for example derives from cattle is suitable.For example, the collagen protein by the Corii Bovis seu Bubali preparation is the combination of type i collagen albumen (85%) and III collagen type (15%).
If use, the chitosan in the material so of the present invention derives from chitin usually.Chitin is by natural biological copolymer that the N-acetyl group-the D-glucosamine units is formed.From the shell of shrimp and Eriocheir sinensis, extract chitin according to known way.Then, for example make chitin partially deacetylated, thereby produce chitosan by handling with 5M-15 M NaOH.Chitinous deacetylated being practically impossible fully, but preferred chitosan is deacetylated at least 50%, and more preferably at least 75% is deacetylated.Chitosan has been used for the Wound healing and bone regeneration of various physical form, for example as solution/gel; Film/membrane; Sponge; Powder or fiber.The chitosan of free alkali form is a swellable, but water insoluble basically under nearly neutral pH, but because of being dissolved in acid at ammonium on the chitosan chain.Can by for example with the dissolubility of the crosslinked reduction chitosan of chloropropylene oxide (epichlorhydrin).In general, the mean molecule quantity as the chitosan by gel permeation chromatography is about 10
5-Yue 10
6
In specific embodiment, described substrate comprises following mixture of ingredients (and being made up of following mixture of ingredients basically): (a) collagen protein and/or chitosan; (b) oxidized regenerated cellulose, for example collagen protein/chitosan: the ORC dry weight than scope about 90: about 10: 90 of 10-, preferred about 75: about 25: 75 of 25-, and particularly about 60: about 40: 60 of 40-.
Wound dressing materials of the present invention can also contain silver salt.Certain silver can be used as argent and exists, but there is the preferably colourless basically silver salt existence of conduct in the major part of preferred silver as silver salt.Silver in the preferred described material mainly is made up of silver salt, more preferably basically by forming as colourless basically silver salt.The amount (as silver ion and argent) of silver is at the about 5wt.% of about 0.01wt%-in the preferred material of the present invention, the about 2wt.% of 0.1wt%-more preferably from about, and the most preferably from about about 1wt.% of 0.1wt.%-, most preferably from about 0.3wt.%.The antibiotic deficiency that is that more a spot of silver can produce.Relatively large silver all wound healing cell produces antiproliferative effect.
For example, described in WO02/43743, can be by with silver salt or be dissolved in or be scattered in water or organic solvent, but introduce silver such as the compound treatment biology absorption base material in the ethanol.Suitable compound comprises silver oxide, siliver chromate, silver allantoinate, boric acid silver, glyceric acid silver (silver glycerolate), silver nitrate, silver acetate, silver chloride, silver sulfate, actol, Silver monobromide, silver iodide, Disilver carbonate, Itrol., lauric acid silver, deoxycholic acid silver, silver salicylate, para-amino benzoic acid silver and composition thereof.Preferred described silver does not exist as silver sulfadiazine.
In preferred embodiments, silver can be compound with host material.Term " complex " refers to and is preferably having the ionic bond between silver and the polymer or an immixture of covalent bond on the molecular level.This complex preferably includes anionic polymer and Ag
+Between the silver that forms.Suitable situation is that described anionic polymer is the polysaccharide of polycarboxylate or poly-Sulfation.Suitable is that described anionic polymer comprises anion polysaccharide.Suitable anion polysaccharide comprises: hyaluronate; Pectin; Carrageenan; Xanthan gum; The polysaccharide sulfate class; Such as dermatan sulfate or sulphation glucosan; And oxidized cellulose.
Can prepare anionic polymer and silver-colored complex by a kind of method, this method comprises the step of handling anionic polymer with silver salt solution.Preferred described solution is aqueous solution.Preferred described anionic polymer is water insoluble basically and down described polymer is handled solid-state thus under Ph7.For example, this polymer can be solid fiber, sheet, sponge or form of fabric.In certain embodiments, described anionic polymer is salt and can regards processing as ion exchange thus.In other embodiments, described anionic polymer to small part is a free acid form, and in this case, preferred silver salt is faintly acid salt, silver acetate for example, and described thus anionic polymer to small part is neutralized by described silver salt.Similar approach is described among the EP-A-0437095, and the full content with the document is incorporated herein by reference especially.
Neutralization reaction can be carried out in independent water or alcohol, but preferably carries out in the mixture of water and alcohols.The application of water and alcohol mixture provides fine solubility by means of water for salt of weak acid, and alcohol has prevented that anionic polymer from excessive swelling, distortion and depletion taking place in N-process.Therefore, the physical characteristic that has kept material.Methanol is preferred alcohol, because manyly in the above-mentioned salt have fine solubility in this alcohol and water.Preferred alcohols has about 4 with the ratio of water: 1-1: 4 scope.If solution excessively is rich in alcohol, some salt may no longer dissolve so, if all the more so when particularly described alcohol is not methanol.If solution excessively is rich in water, so underway and the time polymer to a certain degree swelling can take place, and physical characteristic has to a certain degree loss such as the hot strength of polymer.Other useful alcohols comprises: for example ethanol, propanol and isopropyl alcohol.
Slight nertralizer provides control to degree of neutralization such as the application of silver acetate.Can not produce 100% neutral polymer to anionic polymer applied chemistry amount of calculation and stoichiometric nertralizer and carboxylic acid, because produce strong irreversible reaction, described alkali such as sodium hydroxide, sodium carbonate, sodium bicarbonate and ammonium hydroxide with alkali.
Anionic polymer works as ion-exchanger and the silver-colored cation of any silver salt by them is separated out from solution.The by-product of this exchange is the acid from salt, and produces the weak organic acid that polymer is not had infringement by the salt that uses weak organic acid, such as acetic acid.The salt of strong acid has produced hydrochloric acid or sulfuric acid by-products respectively such as the application of sodium chloride or sodium sulfate, and these strong acid can produce infringement, such as making the polymer depolymerization.
When using faintly acid silver salt, the proton on the Ag ion exchange polymer and the part of salt are converted to weak acid.Acid and the mixture of salt in solution have produced the buffer solution of keeping quite constant pH and controlling degree of neutralization.Equilibrium establishment reaction makes silver ion combine with the acid moieties of polymer thus and combines with molecules of salt.The distribution of this silver ion has prevented that polymer neutralization from carrying out fully.
For example, use the silver acetate of stoichiometric amount to produce the degree of neutralization of hydroxy-acid group on the oxidized cellulose polymer of about 65-75%.This by generating the buffer solution control pH that the oneself produces and using the swollen method of methanol control material to produce the neutral material of part, physical characteristic wherein, for example hot strength and polysaccharide shape are protected.
The amount of used silver salt generally approximates the amount of acid content in the polymer or reaches its 2 times.Perhaps, can use the silver salt of the stoichiometric amount that adds for the second time, condition is after interpolation reaches constant pH for the first time, gives in the reaction system and adds fresh solvent again.Washing has the material of rising pH then, so that from wherein removing excessive silver salt and ion.
In certain embodiments, comprise and silver-colored compound collagen protein to the small part wound dressing materials.Can reach this purpose by handling collagen protein with silver salt solution.For example, silver salt can be about about 0.01 mole-Yue 1 mole silver acetate or silver nitrate for concentration.Preferably under the pH of about 5-about 9, handle.Think that silver nitrogenous side chain main and collagen, amino acid is compound, described collagen, amino acid is lysine, oxylysine, agedoite, glutamine and arginine particularly.Silver can also combine (if existence) with the sulfydryl of methionine and cysteine and combines with the carboxyl of aspartic acid and glutamic acid.
The amount of silver accounts for about 30% weight of about 0.01-of collagen protein weight in the preferred collagen complex, and more preferably from about 0.1%-is about 20%, more preferably from about about 10% weight of 2%-.The preferred amount of silver-collagen complex in wound dressing materials is about the about 10wt.% of about 0.1-, more preferably from about the about 2wt.% of 0.1-.Under any circumstance, the general as above-mentioned appointment of the total amount of silver in wound dressing materials.
Will appreciate that and to prepare the silver with relative high silver content and the complex of above-mentioned host material, for example silver content is greater than 5wt.%, and use other host material (identical or different) dilution then and obtain required total silver content, be 0.01wt.%-5wt.%, the about 2wt% of preferably about 0.2wt.%-.
Material of the present invention can be made pearl, flakes, powder type, and the form of preferred film, fiber mat, net, textile fabric or adhesive-bonded fabric, cryodesiccated sponge, foam or its combination.In certain embodiments, but described solid biologic absorption base is selected from textile fabric, knitted fabric and adhesive-bonded fabric, and they all can prepare according to conventional method.In other embodiments, for example, as mentioned above, but the solid biologic absorption base can comprise the sponge (or being made up of it basically) of cryodesiccated sponge or solvent seasoning.
But described solid biologic absorption base is generally sheet shape, for example has about 1cm
2-Yue 400cm
2, particularly about 2cm
2-Yue 100cm
2The flaky material of area.The basis weight of this sheet generally is about 100g/m
2-Yue 5000g/m
2, for example about 400g/m
2-Yue 2000g/m
2
But solid biologic absorption base material can account for wound dressing materials weight at least about 50%, for example at least about 75% weight or at least about 90% weight.
Term " dyestuff " is promptly at the organic compound of the strong extinction of visible region of 400-700nm.In certain embodiments, described antioxidant dyestuff is selected from aniline dyes, acridine dye, thionine class dyestuff, two-naphthalocyanine dye, thiazin dyes, azo dyes, anthraquinone class and composition thereof.For example, described antioxidant dyestuff can be selected from gentian violet, aniline blue, methylene blue, crystal violet, acriflavine, 9-aminoacridine, acriflavinium chloride, acridine orange, proflavine, quinacrine, viride nitens, trypan blue, trypan red, peacock green, azepine atabrine, gentian violet, methyl orange, methyl yellow, ethyl violet, acid orange, Indian yellow, acid blue, Xylene Red, thioflavin, Alphazurine, indigo, methylene green and composition thereof.
These dyestuffs can also make the silver salt that is present in the described material keep stable with the decomposition of antagonism photochemistry by the light that absorbs near material surface, particularly resist photoreduction and become argent.The free radical that the further capture light chemistry of these dyestuffs produces, otherwise these free radicals just may be given birth to reaction with silver hair.In this manner, dyestuff can play photochemical desensitisers.Except that above-mentioned common dyes, but the organic desensitizer that is used for metal in the medical treatment of photography type can be suitable for the dyestuff as material of the present invention.
Described dyestuff may reside in the wound dressing materials of the present invention, and its consumption accounts for the about 5wt.% of about 0.05%-of material dry weight, generally is about the about 2wt.% of 0.2-.
Described wound dressing materials can also comprise and is up to 20% weight, preferably is lower than the water of 10% weight.This material can also contain 0-40% weight, the plasticizer of preferred 0-25% weight, and preferred polyol is such as glycerol.This material can also comprise 0-10% weight, one or more therapeutic wound healing agent of preferred 0-5% weight are such as nonsteroid anti-inflammatory drugs (for example acetaminophen), steroid, antibiotic (for example penicillins or streptomycin class), antiseptic (for example silver sulfadiazine or chlorhexidine) or somatomedin (for example fibroblast growth factor or platelet-derived somatomedin).All above-mentioned percentage ratios are all with dry weight basis.
Wound dressing materials of the present invention preferably aseptic and be packaged in the microorganism impervious container.
The free radical activity that preferred material of the present invention has in diphenylpicrylhydrazyl (DPPH) test, promptly antioxidant activity is at least about 15%, and it is determined as polysaccharide 10
-4In the 0.5%w/v dispersion liquid among the MDPPH after 4 hours at the absorbance decline percentage ratio at 524nm place, as further described in the operation 1 hereinafter.Preferably in DPPH test absorbance decline percentage ratio (with dyestuff to any absorbance calibration after) be at least about 25%, more preferably be at least about 50%, and most preferably be at least about 75%.
On the other hand or in addition, material of the present invention can show antioxidant activity, as determined by suppressing peroxidase to the ability of ABTS (2,2 '-azine group-two-[3-ethyl benzo thiazole phenanthroline sulphonic acid ester]) oxidation by it.
Preferred material of the present invention suction or wound fluid and become moistening, swelling thus or become gluey group, but can spontaneous dissolving therein or disperse.Be that it is hydrophilic, but the dissolubility in the water under 25 ℃ preferably is lower than about 1g/ liter.Low solubility makes this class material be particularly suitable for as the wound dressing of removing reactive oxygen species from the wound fluid.
The antioxidant of material of the present invention and antibacterial characteristics have been pointed out the medical applications of certain limit, comprise ulcer and other chronic or gangrenosum acne wound and the inflammation infringement and the disease of treatment of acute surgical and traumatic wounds, burn, fistula, varicosis star ulcer, ulcer of artery, pressure ulcer (otherwise being called decubital ulcer), diabetic ulcer, mixed etiology.Material of the present invention is used for the treatment of the wound (promptly not showing the wound that infects sign) of infection and non-infection.
Therefore, the present invention provides in aspect second material of the present invention to be used for the treatment of application in the medicine of wound in preparation.Preferred described wound is a chronic wounds.More preferably described chronic wounds is selected from ulcer, decubital ulcer or the diabetic ulcer of venous ulcer, ulcer of artery or mixed etiology.Preferred described material is used as the antioxidant that alleviates the oxidative stress in the wound environment and promote wound healing thus.
The present invention provides the method for treatment mammal wound in related aspect, comprise the material of the present invention to its administering therapeutic effective dose.Preferred described wound is a chronic wounds.
The present invention provides the wound dressing that comprises antioxidant wound dressing materials of the present invention in aspect the 3rd.
Described wound dressing is preferably sheet shape and comprises the active component layer of material of the present invention.The active component layer is generally the wound contact layer in application, but in certain embodiments, it can separate from wound by the upper sheet that can see through liquid.The area of preferred active component layer is at about 1cm
2-Yue 400cm
2, 4cm more preferably from about
2-Yue 100cm
2
Preferred described wound dressing further comprises and the mount backing layer of active component aspect to expanding on the relative active component layer in the side of wound.The preferred described backing layer of mounting is greater than the active component layer, makes 1mm-50mm, the marginal zone of preferred 5mm-20mm thickness expand on the active component layer and forms so-called dressing island.In this class situation, preferably be coated on the marginal zone at least of mounting backing layer with pressure sensitive medical grade adhesive.
The preferred described backing layer of mounting is can not see through liquid basically.This is mounted backing layer and is preferably semipermeable.Promptly but this mounts the preferred permeate water steam of backing layer, but can not see through liquid water or wound fluid.Preferred this mounted backing layer and can not be seen through microorganism.Suitable uninterrupted concordance is mounted the moisture vapor transmission rate of mounting backing layer separately (MVTR) that backing layer preferably has and be 300-5000g/m under 37.5 ℃ and 100%-10% relative humidity difference
2/ 24 hours, preferred 500-2000g/m
2/ 24 hours.The thickness of mounting backing layer is preferably in the scope of 10-1000 micron, more preferably the 100-500 micron.Have been found that this class moisture vapor transmission rate makes the wound under the dressing heal under wet condition, and the skin of wound circumference is macerated.
Silver salt forms the suitable polymers of mounting backing layer and comprises polyurethanes and poly-alkoxyalkyl esters of acrylic acid and methyl acrylic ester, such as those disclosed among the GB-A-1280631.The preferred described uninterrupted layer that is mainly closed chamber that backing layer comprises the polyurethane foam of high-density block of mounting.The suitable backsheet of mounting is that registered trade mark is the polyurethane film of ESTANE5714F.
Binding agent (if exist) layer should transmit dampness and/or form a fixed structure so that steam from wherein passing through.Adhesive phase is preferably the pressure sensitive adhesive layer of the continual transmission dampness that is usually used in island type wound dressing, for example, and based on for example contact adhesive of acrylate copolymer described in the GB-A-1280631, polyvinyl ethyl ether and polyurethanes.The basis weight of adhesive phase is preferably 20-250g/m
2, and preferred 50-150g/m
2Be preferably based on the contact adhesive of polyurethanes.
Can between active component layer and overcoat, set up other layer of multilayer absorbent article.For example, these layers comprise the absorbed layer between active component layer and the overcoat, if especially dressing is used ooze out make on the wound all the more so.Optionally absorbed layer can comprise gauze, adhesive-bonded fabric, superabsorbents, hydrogel and composition thereof for being usually used in absorbing the random layer of wound fluid, serum or blood in the wound healing field.Preferred described absorbed layer comprises layer of absorbent foam, such as according to EP-A-0541391 preparation open cell-type hydrophilic polyurethane foam, the full content with the document is incorporated herein by reference especially.In other embodiments, absorbed layer can be nonwoven fiber mesh material, for example the carded net of viscose staple fibre.The basis weight of absorbed layer can be at 50-500g/m
2Scope, such as 100-400g/m
2Unpressed absorber thickness can be in the scope of 0.5mm-10mm, such as 1mm-4mm.Freedom (unpressed) the Liquid Absorption energy of under 25 ° normal saline being measured can be in the scope of 5-30g/g.Preferred absorbed layer or many absorbed layers extend in time jointly with the active component layer basically.
Described dressing is preferably protected by removable cover layer towards the surface of wound.This cover layer is formed by flexible thermoplastic usually.Suitable material comprises polyesters and TPO.Preferred cover layer face is a release surface to the surface of adhesive layer.Promptly should the surface only so that help adhesive layer be peeled off from cover layer with mounting to adhere to a little less than active component layer on the backing layer and the adhesive layer.For example, cover layer can be formed such as fluoropolymer polymer by NA plastics, maybe can apply release coat to it, such as siloxanes or fluoropolymer polymer release coat.
In general, wound dressing of the present invention is sterile and packaged in the microorganism impervious container.
The present invention provides the method for preparing antioxidant wound dressing materials in one aspect of the method, but comprises the step with suitable dyeing biology absorption base material.This method preferably further comprises with the silver salt that is dissolved in or is scattered in water or the organic solvent handles host material.
Method of the present invention can be used to prepare wound dressing of the present invention.
Method of the present invention can comprise: by the host material with sheet shape, for example the textile fabric of host material, adhesive-bonded fabric or knitted fabric or sponge are immersed dye bath it is dyeed, and be removing unconjugated dyestuff, and dry with after scouring.In other embodiments, can dye to host material, and it is fiber or particle form, makes this material form sheet subsequently.For example, can handle the fiber of host material or particulate slurry and form painted sponge then with dyestuff.Can carry out silver after removing the step of combination dye not handles.
Be appreciated that any feature relevant with any one aspect of the present invention described herein or embodiment equally also go for any others of the present invention.
In the following example, further describe some specific embodiments of the present invention now.
Embodiment 1
Be prepared as follows antioxidant wound dressing materials based on the cryodesiccated wound dressing materials of collagen protein/ORC.
Following corium by cattle prepares the collagen protein composition.Peel off cattle corium from Corii Bovis seu Bubali, scraping is also immersed liquor natrii hypochloritis (0.03%w/v), so that be suppressed at the microbial activities in the further course of processing.Wash corium then with water and use and contain the solution-treated of sodium hydroxide (0.2%w/v) and hydrogen peroxide (0.02%w/v), so that make corium swelling and sterilization at ambient temperature.Make the corium overburden under greater than 12.2 pH, ambient temperature and containing in 10-14 days time limits in the solution of sodium hydroxide, calcium hydroxide and sodium bicarbonate (being respectively 0.4%w/v, 0.6%w/v and 0.05%w.v) and carry out alkali treatment subsequently, upset is lower than 0.24mmol/g up to the level that reaches amide nitrogen simultaneously.Under ambient temperature and pH0.8-1.2, the corium overburden is carried out acid treatment step then with 1% hydrochloric acid.Processing is continued to proceed to the corium overburden with upset has adsorbed the acid of capacity and has reached pH less than 2.5.Use then overburden washed to the pH value of corium overburden and reach 3.0-3.4.Subsequently in the cartridge type chipper by slightly smashing to pieces for the first time the corium overburden with carefully smashing to pieces that ice is smashed to pieces and set then.Freezing and store the gained pastel, after this it be used for next procedure of processing by 650g corium overburden and the composition of proportions of (as icing) of 100g water.But, in next step with before ORC and other composition mix, collagen protein is not carried out lyophilization.
Be prepared as follows the ORC composition of freeze-dried pad.Use rotary knife cutter to grind SURGICEL cloth (Johnson ﹠amp by sieve plate; Johnson Medical Arlington), is being lower than 60 ℃ with temperature maintenance.
Introduce dyestuff to reach final solid concentration be 1% by an amount of acid stain methylene blue being dissolved in 0.05M acetic acid and joining in the collagen paste that contains ground ORC powder.The preparation sample is wherein introduced serosity with following concentration with dyestuff: 0% (reference example), 1mg/ml, 0.5mg/ml and 0.1mg/ml.
In the culture dish that gained serosity impouring 3mm is dark, place it on the shelf of cold closet, wherein temperature is set in advance in-40 ℃.The program that starts freeze dryer then is so that dry collagen protein and ORC and make device dehydrogenation heat cross-linking and form foam-rubber cushion.When circulation is finished, discharge vacuum, pack sponge sample then and use cobalt 60 γ irradiation sterilizations.
Embodiment 2
Operate according to embodiment 1, but replace MBD with basic stain crystal violet.With following concentration crystal violet is introduced serosity: 0% (reference example), 1mg/ml, 0.5mg/ml and 0.1mg/ml.
Embodiment 3
Operate according to embodiment 1, but with basic stain flavin 3,6-proflavin Hemisulphate replaces MBD.With following concentration flavin is introduced serosity: 0% (reference example), 1mg/ml, 0.5mg/ml and 0.1mg/ml.
Embodiment 4
Operate according to embodiment 1, but with basic stain flavin 3,6-proflavin Hemisulphate replaces MBD.With following concentration flavin is introduced serosity: 0% (reference example), 1mg/ml, 0.5mg/ml and 0.1mg/ml.
Embodiment 5
Operate according to embodiment 1, but with methylene blue and flavin 3, the mixture of 6-proflavin Hemisulphate replaces MBD, every kind of dyestuff is introduced serosity with the concentration of 0.5mg/ml.
Embodiment 6
Operate according to embodiment 1, but with crystal violet and flavin 3, the mixture of 6-proflavin Hemisulphate replaces MBD, every kind of dyestuff is introduced serosity with the concentration of 0.5mg/ml.
Embodiment 7
Operate according to embodiment 1, but replace MBD, every kind of dyestuff is introduced serosity with the concentration of 0.5mg/ml with the mixture of crystal violet and methylene blue.
Embodiment 8-14
Through the following steps silver is introduced the wound dressing materials for preparing described in embodiment 1-7: silver acetate is dissolved in 0.05M acetic acid also this solution is joined in the ORC/ collagen protein serosity, with the total solid is benchmark, and its introducing amount is enough to produce the final serosity that contains 1wt.% silver.
The sponge of the present invention that obtains among the embodiment 1-14 all shows the stable absorption to dyestuff.Serum a couple of days under these sponges can being immersed 25 ℃ and they keep coloured from start to finish.According to the difference of the dye strength that adds, excessive dyestuff begins to discharge and progressively discharge when sponge begins to degrade then.
Operation 1
By in the reaction of the test evaluation wound dressing materials of DPPH described in the WO94/13333 and oxygen radical and remove their ability, the full content with the document is incorporated herein by reference especially.This test adopt from Blois M.S. " nature " (
Nature) 181:1199 (1958) and Banda P.W. etc. " analysis communication " (
Analytical Letters) test described in the 7:4l (1974).
Briefly, with the wound dressing materials (2.5mg in the test; 5mg; ﹠amp; The 25mg sample size) is suspended in the 2.5ml 0.1M pH7.0 phosphate buffer.Adding consumption is the solution (10 of diphenylpicrylhydrazyl (DPPH) in methanol of 2.5ml
-4M) and this mixture of jolting and being stored in 20 ℃ of following dark.Assess sample through the following steps: in 6 hours, measure its absorbance at 524nm place and with the reference substance comparison, pay special attention to the figure after 4 hours.The absorbance of comparing with reference substance after 4 hours reduces percentage ratio and has drawn the DPPH test value, and repeatability is generally 5%.Can represent this value expediently according to the simple minimizing of the absorbance unit of comparing with reference substance (AU).
Ascorbic acid is well-known antioxidant, and it provides useful positive control substance for the contrast purpose.The sponge of cryodesiccated chitin/chitosan and hydroxyethyl-cellulose is used as negative control.
The material of the present invention that this test is applied to embodiment 1-7 is 80-90% (10 to the DPPH test value that positive control produces
-4M).On the contrary, negative control chitin/chitosan and hydroxyethyl-cellulose show the far away low DPPH value less than 15%.Collagen protein/ORC that cloth adds any dyestuff shows certain activity in the DPPH test, show that ORC self has certain antioxidant properties.Coloring material of the present invention shows apparently higher than the activity of independent collagen protein/ORC in the DPPH test, and this result is consistent with the antioxidant activity of described dyestuff.
Operation 2
By observing the bacteriostatic activity of inhibition zone to the sponge for preparing among Pseudomonas aeruginosa (pseudomonas Aeruginosa) and the routine 8-14 of staphylococcus aureus (staphylococcus Aureus) test implementation.
Under aseptic condition, downcut 6 2cm * 2cm square of every duplicate samples.When the 1st day of this experiment, the culture of Pseudomonas aeruginosa (ATCC 27853 and various PSI bacterial strain) and staphylococcus aureus (providing (Dept of ClinicalMicrobiology and Pathology) by the clinical microbiology and the pathology department of the Chinese Academy of Sciences) is being incubated 24 hours in aerobic mode down and on the diagnostic sensitivity agar (DSA) at 37 ℃.After 24 hours, specimen is placed on the DSA flat board separately and soaks with 0.5mls buffer solution at once.Three squares of sample are placed on the flat board of having inoculated Pseudomonas aeruginosa and with three squares are placed on the flat board of having inoculated staphylococcus aureus.Then flat board is incubated 24 hours down at 37 ℃.Use subsequently and suppress the band of growth around the caliper measuring samples and specimen is placed on the DSA flat board of new inoculation.Swab test is carried out in zone under the sample, so that it is by swab being smeared on the DSA flat board and it being incubated 24 hours and checking growing state to determine that sample is a bacteriostatic then, still germ-resistant.Sample is forwarded on the flat board of inoculation recently,, just carried out one time aforesaid operations, continue 72 hours every 24 hours as long as sample is kept perfectly.
As negative control, test does not contain the cryodesiccated 45%ORC/55% collagen protein sponge of any silver or dyestuff.With silver-containing antibacterial dressing (ACTICOAT, the Smith﹠amp that is purchased; The registered trade mark of Nephew) and silver nitrate solution (0.5%) as positive control and in duration of trial, both are observed the inhibition situation.
Discovery is observed remarkable bactericidal action to staphylococcus aureus and Pseudomonas aeruginosa to material of the present invention.The performance of estimating to contain the performance of material of 1% silver medal and mentioned component and ACTICOAT dressing is suitable.
Only above-mentioned embodiment is described by embodiment.Many other embodiments that belong in the claim scope that awaits the reply are apparent to those skilled in the art.
Claims (19)
1. wound dressing materials is used the painted solid biologic absorption base of antioxidant dyestuff but it comprises.
2. the wound dressing materials of claim 1, wherein said substrate comprises the solid biologic absorbable material, and this material is selected from collagen protein, oxidized cellulose, chitosan, galactomannan, glycosaminoglycans, polylactide/poly-Acetic acid, hydroxy-, bimol. cyclic ester and composition thereof.
3. the wound dressing materials of claim 2, wherein said substrate comprises the solid biologic absorbable material, this material is selected from collagen protein, oxidized regenerated cellulose, chitosan and composition thereof.
4. the wound dressing materials during arbitrary aforesaid right requires, but wherein said solid biologic absorption base is selected from the sponge and the combination thereof of fibrous woven fabric, knitted fabric, adhesive-bonded fabric, cryodesiccated sponge, solvent seasoning.
5. the wound dressing materials during arbitrary aforesaid right requires, wherein said antioxidant dyestuff are selected from aniline dyes, acridine dye, thionine class dyestuff, two-naphthalocyanine dye, thiazin dyes, azo dyes, anthraquinone class and composition thereof.
6. the wound dressing materials during arbitrary aforesaid right requires, wherein said antioxidant dyestuff are selected from gentian violet, aniline blue, methylene blue, crystal violet, acriflavine, 9-aminoacridine, acriflavinium chloride, acridine orange, proflavine, quinacrine, viride nitens, trypan blue, trypan red, peacock green, azepine atabrine, gentian violet, methyl orange, methyl yellow, ethyl violet, acid orange, Indian yellow, acid blue, Xylene Red, thioflavin, Alphazurine, indigo, methylene green and composition thereof.
7. the wound dressing materials during arbitrary aforesaid right requires, the amount of wherein said antioxidant dyestuff accounts for the about 2wt.% of about 0.2-of this material dry weight.
8. the wound dressing materials during arbitrary aforesaid right requires, wherein said material also comprises silver salt, wherein said dyestuff makes this silver salt fast light.
9. the wound dressing materials of claim 8, wherein polymeric matrix comprises anionic polymer, and described silver salt comprises the salt that Ag+ and anionic polymer form.
10. claim 8 or 9 wound dressing materials, wherein based on the dry weight basis of said composition, said composition comprises the silver of the about 5wt.% of about 0.01wt.%-.
The wound dressing materials during 11. arbitrary aforesaid right requires, wherein said material is a sheet shape.
12. the wound dressing materials during arbitrary aforesaid right requires, wherein said material are aseptic and are packaged in the microorganism impervious container.
The wound dressing materials during 13. arbitrary aforesaid right requires, the free radical activity that wherein said material has in diphenylpicrylhydrazyl (DPPH) test of as defined herein antioxidant activity is at least about 15%.
14. each material is used for the treatment of application in the medicine of wound in preparation among the claim 1-13.
15. the application of claim 14, wherein said wound is a chronic wounds, is preferably selected from the ulcer of varicose ulcer, decubital ulcer or diabetic ulcer.
16. prepare the method for antioxidant wound dressing materials, but comprise step with antioxidant dyestuff dyeing biology absorption base material.
17. being used for of claim 16 prepares each the method for wound dressing materials of claim 1-13.
18. wound dressing, it comprises among the claim 1-13 each antioxidant wound dressing materials.
19. the wound dressing of claim 18, wherein said material are aseptic and are packaged in the microorganism impervious container.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314454A GB2402882B (en) | 2003-06-20 | 2003-06-20 | Antioxidant wound dressing materials |
| GB0314454.0 | 2003-06-20 | ||
| US60/491,991 | 2003-08-04 | ||
| GB0326844.8 | 2003-11-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1838970A true CN1838970A (en) | 2006-09-27 |
| CN100471527C CN100471527C (en) | 2009-03-25 |
Family
ID=27637053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004800238156A Expired - Fee Related CN100471527C (en) | 2003-06-20 | 2004-06-21 | Antioxidant wound dressing materials |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN100471527C (en) |
| GB (1) | GB2402882B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421461A (en) * | 2009-03-23 | 2012-04-18 | 利兹大学 | Scaffold |
| CN102596560A (en) * | 2009-11-09 | 2012-07-18 | 3M创新有限公司 | Medical articles and methods of making using miscible composition |
| CN102686249A (en) * | 2009-11-09 | 2012-09-19 | 3M创新有限公司 | Medical articles and methods of making using immiscible material |
| CN107638306A (en) * | 2016-07-21 | 2018-01-30 | 卢乃宏 | Skin care products effective ingredient method for concentration |
| CN107921169A (en) * | 2015-08-21 | 2018-04-17 | Qr肌肤有限公司 | The composition and product comprising senile cell used in regeneration |
| CN109416355A (en) * | 2016-03-30 | 2019-03-01 | 定性酶诊断有限责任两合公司 | Detect wound microbes infection |
| CN110478533A (en) * | 2019-09-06 | 2019-11-22 | 董英 | Medical discoloration antibacterial agent and its application |
| CN114306726A (en) * | 2021-12-17 | 2022-04-12 | 广西萌大夫生物技术有限公司 | Preparation method and use method of injectable bionic antioxidant hydrogel |
| CN114887114A (en) * | 2022-04-24 | 2022-08-12 | 中山大学附属第八医院（深圳福田） | Cascade antibacterial and bone-promoting titanium-based metal material and preparation method and application thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2408206B (en) * | 2003-11-18 | 2007-11-28 | Johnson & Johnson Medical Ltd | Antioxidant and antimicrobial wound dressing materials |
| EP1799276B1 (en) * | 2004-10-07 | 2017-05-03 | Ngen Pharmaceuticals N.V. | Composition for treating wounds and burns |
| US20060182981A1 (en) * | 2005-02-16 | 2006-08-17 | Debergalis Michael | Antimicrobial fluoropolymer film, laminates and articles and process for making thereof |
| GB2433029A (en) * | 2005-12-09 | 2007-06-13 | Ethicon Inc | Wound dressings comprising oxidized cellulose and human recombinant collagen |
| EP3562520B1 (en) * | 2016-12-28 | 2022-08-10 | Systagenix Wound Management, Limited | Antimicrobial wound dressings |
| WO2021014357A1 (en) * | 2019-07-23 | 2021-01-28 | Kci Licensing, Inc. | Collagen-based biomaterials for wound management |
| KR20230160364A (en) * | 2021-03-24 | 2023-11-23 | 케레시스 에이치에프 | Pigmented biological wound treatment provides monitoring of healing progress |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB570428A (en) * | 1942-12-30 | 1945-07-06 | Lederle Lab Inc | Improvements in surgical dressings of sulphonamides |
| GB619165A (en) * | 1946-11-23 | 1949-03-04 | John Thomas Gillison | An improved surgical material |
| GB2134781B (en) * | 1983-02-15 | 1986-02-12 | Diomed Dev Ltd | Composition for the treatment of stasis leg ulcers |
| US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| EP0560014A1 (en) * | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
| DE19712699C2 (en) * | 1997-03-26 | 2000-05-25 | Thueringisches Inst Textil | Process for the production of wound dressings with wound care active substances |
| AUPQ419099A0 (en) * | 1999-11-23 | 1999-12-16 | Ko, Thomas Sai Ying | Novel compositions and methods |
| GB0025084D0 (en) * | 2000-10-13 | 2000-11-29 | Cambridge Meditech | Improvements in detection |
-
2003
- 2003-06-20 GB GB0314454A patent/GB2402882B/en not_active Expired - Fee Related
-
2004
- 2004-06-21 CN CNB2004800238156A patent/CN100471527C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421461A (en) * | 2009-03-23 | 2012-04-18 | 利兹大学 | Scaffold |
| CN102596560A (en) * | 2009-11-09 | 2012-07-18 | 3M创新有限公司 | Medical articles and methods of making using miscible composition |
| CN102686249A (en) * | 2009-11-09 | 2012-09-19 | 3M创新有限公司 | Medical articles and methods of making using immiscible material |
| CN102596560B (en) * | 2009-11-09 | 2015-11-25 | 3M创新有限公司 | Medical article and the method using miscible composition to be prepared |
| CN107921169A (en) * | 2015-08-21 | 2018-04-17 | Qr肌肤有限公司 | The composition and product comprising senile cell used in regeneration |
| CN109416355A (en) * | 2016-03-30 | 2019-03-01 | 定性酶诊断有限责任两合公司 | Detect wound microbes infection |
| US11740241B2 (en) | 2016-03-30 | 2023-08-29 | Synovo Gmbh | Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds |
| CN107638306A (en) * | 2016-07-21 | 2018-01-30 | 卢乃宏 | Skin care products effective ingredient method for concentration |
| CN110478533A (en) * | 2019-09-06 | 2019-11-22 | 董英 | Medical discoloration antibacterial agent and its application |
| CN114306726A (en) * | 2021-12-17 | 2022-04-12 | 广西萌大夫生物技术有限公司 | Preparation method and use method of injectable bionic antioxidant hydrogel |
| CN114887114A (en) * | 2022-04-24 | 2022-08-12 | 中山大学附属第八医院（深圳福田） | Cascade antibacterial and bone-promoting titanium-based metal material and preparation method and application thereof |
| CN114887114B (en) * | 2022-04-24 | 2023-04-07 | 中山大学附属第八医院（深圳福田） | Cascade antibacterial and bone-promoting titanium-based metal material and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2402882B (en) | 2007-03-28 |
| CN100471527C (en) | 2009-03-25 |
| GB2402882A (en) | 2004-12-22 |
| GB0314454D0 (en) | 2003-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10143771B2 (en) | Antioxidant and antimicrobial wound dressing materials | |
| Yuan et al. | Chitosan, alginate, hyaluronic acid and other novel multifunctional hydrogel dressings for wound healing: A review | |
| CA2529413C (en) | Antioxidant wound dressing materials | |
| CN100471527C (en) | Antioxidant wound dressing materials | |
| CN110354295B (en) | Photo-thermal conversion material and preparation method thereof | |
| AU2005329351B2 (en) | The preparing method and the use of antiseptic medical dressing. | |
| CA2524184C (en) | Microbial cellulose wound dressing comprising phmb | |
| CZ22394U1 (en) | Antimicrobial mixture and cover to support healing of wounds with antimicrobial effect | |
| KR102012581B1 (en) | Patch-type wound dressing comprising methylene blue mixture for treating skin wound | |
| Liang et al. | Natural hydrogel dressings in wound care: Design, advances, and perspectives | |
| Huang et al. | Metal-organic framework-based dressings: Application and opportunities in wound healing | |
| JP4896714B2 (en) | Antioxidant wound dressing material | |
| CN102008740B (en) | Absorbable growth factor composite dressing | |
| CN1723778A (en) | Silver-contg. type antibiotic agent, prepn. method and application thereof | |
| CN114129764A (en) | Multifunctional hydrogel and preparation method thereof | |
| RU2568909C2 (en) | Medical dressing, method for producing and using it | |
| CN115554458B (en) | Loofah sponge-based lysozyme antibacterial dressing and preparation method thereof | |
| CN111821504B (en) | Silver ion disinfection gel and preparation method thereof | |
| CN114712547B (en) | Bacterial cellulose-based photosensitive antibacterial dressing and preparation method and application thereof | |
| CN112915252A (en) | Chitosan quaternary ammonium salt derivative wound dressing and preparation method thereof | |
| CN117695436A (en) | Gallic acid modified bletilla striata polysaccharide hydrogel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090325 |